H+/K+-ATP酶抑制剂苯并咪唑类衍生物的研究
作者:黄国宾 程卯生 黄惠琴 沈建民1
单位:沈阳药科大学科研处合成二室,沈阳 110015
关键词:H+/K+-ATP酶抑制剂;苯并咪唑类衍生物;抑制胃酸分泌
中国药物化学杂志/990203摘 要 H+/K+-ATP酶是胃酸分泌的最后环节,在合成H+/K+-ATP酶抑制剂泮托拉唑的基础上,设计合成了12个未见文献报道的苯并咪唑类衍生物,经红外光谱、核磁共振氢谱和元素分析确定了结构.初步药理筛选实验表明:化合物(5b),(6b),(6d)具有抑制胃酸分泌的作用,其中化合物(6d)作用最强.
Studies on H+/K-ATPase Inhibitors Benzimidazole Derivatives
, 百拇医药
Huang Guobin,Cheng Maosheng,Huang Huiqing,Shen Jianmin
Institute of Materia Medica,Shenyang Pharmaceutical University,Shenyang 110015
Abstract H+/K-ATPase is the last passageway of gastric acid secretion.On the basis of synthesis of the H+K-ATPase inhibitor pantoprazole,twelve benzimidazole derivatives were synthesized for the first time,and their structures were proved by IR,1H-NMR and elementary analysis.Their antisecretory activities were evaluated in vivo,the compounds (5b),(6b) and (6d) have antisecretory activities and compound (6d) was the most potent.
, 百拇医药
Key words H+K-ATPase inhibitors;benzimidazole derivatives;inhibiting gastric acid secretion
消化性溃疡疾病是常见的多发病之一,它与胃酸分泌过多有着直接的关系,迅速有效地抑制胃酸分泌是目前治疗消化性溃疡疾病的重要手段〔1〕.胃酸的分泌是由于胃壁细胞膜上的毒蕈碱受体(MR)、胃泌素受体(GR)和组胺H2受体(H2R)分别受到乙酰胆碱、胃泌素和组胺的刺激,引起胃壁细胞分泌胃酸〔2,3〕.分泌出的胃酸必需依靠H+/K+-ATP酶的转运功能把胃壁细胞中的H+转运到胃腔中形成胃酸〔4〕.因此,抑制H+/K+-ATP酶的活性就能有效地控制胃酸分泌.国内外对H+/K+-ATP酶抑制剂进行了广泛的研究,先后上市了奥美拉唑(omeprazole,1)、兰索拉唑(lansoprazole,2)和泮托拉唑(pantoprazole,3),从这三种药物的化学结构看,它们均是吡啶甲基亚磺酰基苯并咪唑类化合物,其本身并无抑制H+/K+-ATP酶的活性,
, 百拇医药
只是在酸性条件下质子化,转变为具有抑制H+/K+-ATP酶活性的化合物次磺酰胺(sulphenamide),它迅速与H+/K+-ATP酶上的半胱氨酸的巯基结合形成二硫键,从而使酶失活〔5〕.研究发现,吡啶环上取代基对活性影响较大,凡能增加吡啶环pKa值的基团将能增加化合物的活性,但pKa值的增加会使作用的靶位专一性降低.由于对苯并咪唑环上的取代基对活性的影响研究较少,因此,本文在合成泮托拉唑的基础上,保留其基本结构,只改变苯并咪唑5-位取代基,用N-取代氨甲酰基[R1R2NC(O)—]代替二氟甲氧基[F2HCO—],设计合成了12个未见文献报道的化合物,以期找到比较稳定和活性高的化合物.合成路线见图1.
, 百拇医药
Fig.1 The route of synthesis of benzimidazole derivatives
1 合成实验
熔点用毛细管法测定,温度未校正.核磁共振氢谱用Bluker AXR-300测定.红外光谱用Bluker IFS 55测定.元素分析用Carlo Erba 1106测定.柱色谱硅胶为青岛海洋化工厂产品.
1.1 3,4-二氨基-N-取代苯甲酰胺(1a~1f)的制备
按文献[6]的方法制备.
1.2 2-巯基-5-取代氨甲酰基-1H-苯并咪唑(2a~2f)的制备
将化合物(1a~1f)0.01 mol加至0.01 mol氢氧化钾、5 mL水和20mL乙醇组成的混合液中,加入二硫化碳0.8 mL,加热回流4 h.用2 mol/L盐酸调pH 3~4,抽滤,粗品用乙醇重结晶,得白色固体.化合物(2a):mp 250℃以上,收率为50.3%;化合物(2b):mp 250℃以上,收率为84.2%;化合物(2c):mp 200~202℃,收率为42.3%;化合物(2d):mp 236~237℃,收率为80%;化合物(2e):mp 231~232℃,收率为37.4%;化合物(2f):mp 228~230℃,收率为75.9%.
, 百拇医药
1.3 2-氯甲基-3,4-二甲氧基吡啶盐酸盐(4)的制备
按文献〔7〕的方法制备.
1.4 5-(N-取代)氨甲酰基-2-[[(3′,4′-二甲氧基-2′-吡啶基)-甲基]-巯基]-1H-苯并咪唑(5a~5f)的合成
将化合物(2a~2f)0.022 mol及化合物(4)0.022 mol加至1.94 g(0.0484 mol)氢氧化钠的30 mL乙醇溶液中,加热回流6 h.减压蒸去乙醇,二氯甲烷萃取(30 mL×3),无水硫酸钠干燥,减压浓缩,残余物经硅胶柱层析[展开剂:氯仿-甲醇(v∶v=95∶5)]得白色固体.熔点、收率和波谱数据见表1.
1.5 5-(N-取代)氨甲酰基-2-[[(3′,4′-二甲氧基-2′-吡啶基)-甲基]-亚磺酰基]-1H-苯并咪唑(6a~6f)的合成
, 百拇医药
将化合物(5a~5f)0.01 mol溶于20 mL氯仿中,磁力搅拌,冰盐浴冷至-10℃,滴加1.73 g(0.01 mol)间氯过氧苯甲酸的10 mL氯仿溶液,反应5 h.依次加入1 mL三乙胺、5 mL 10%硫代硫酸钠溶液和5 mL饱和碳酸钠溶液,搅拌10 min,分取有机层.水洗,饱和碳酸钠溶液(20 mL)洗,无水硫酸钠干燥,浓缩,残余物经硅胶柱层析[展开剂:氯仿-甲醇(v∶v=95∶5)]得白色固体.熔点、收率和波谱数据见表1.
Tab.1 The physical data and spectrum data of compounds(5a~5f)and(6a~6f) Compd.
Yield/%
mp/℃
IR(KBr)/cm-1
, 百拇医药
1H-NMR(CDCl3,TMS)δ
Formula
Elemental analysis/%(Found/Calc.)
C
N
H
5a
62.5
137~138
3357,2942,1640,1415
3.04(d,3H,4.8 Hz,—NCH3),3.94(s,3H,3′-OCH3),3.96(s,3H,4′-OCH3),4.42(s,2H,—SCH2),6.43(br s,1H,—CONH—),6.88(d,1H,5.67 Hz,5′-H),7.52(d,1H,8.37 Hz,7-H),7.59(dd,1H,8.37,0.9 Hz,6-H),8.01(d,1H,0.9 Hz,4-H),8.26(d,1H,5.67 Hz,6′-H),12.1(br s,1H,—NH—)
, 百拇医药
C17H18N4O3S
56.96
(56.80
5.07
5.13
15.66
15.60)
6a
40.1
165~167
3385,1642,1071
, 百拇医药
3.04(d,3H,4.74 Hz,—NCH3),3.86(s,3H,3′-OCH3),3.87(s,3H,4′4′-OCH3),4.84(dd,2H,12.96 Hz,—SOCH2),6.70(br s,1H,—CONH—),6.79(d,1H,5.61 Hz,5′-H),7.57(d,1H,7.17 Hz,7-H),7.69(d,1H,7.17 Hz,6-H),7.99(s,1H,4-H),8.13(d,1H,5.61 Hz,6′-H),12.3(br s,1H,—NH—)
C17H18N4O4S
54.53
(54.50
4.85
, http://www.100md.com
4.91
14.97
14.86)
6b
38.4
105~106
3300,2973,1634,1067
1.30[d,6H,6.54 Hz,(CH3)2C—],3.85(s,3H,3′-OCH3),3.86(s,3H,4′-OCH3),4.30(m,1H,—CH—),4.82(dd,2H,13.05 Hz,—SOCH2),6.17(d,1H,7.56 Hz,—CONH—),6.78(d,1H,5.58 Hz,5′-H),7.60(d,1H,8.37 Hz,7-H),7.69(d,1H,8.37 Hz,6-H),8.01(s,1H,4-H),8.14(d,1H,5.58 Hz,6′-H),12.5(br s,1H,—NH—)
, 百拇医药
C19H22N4O4S
56.69
(56.73
5.51
5.43
13.93
13.96)
5c
70.0
60~61
3427,2981,2873,1617,1439
, http://www.100md.com
1.20[br s,6H,(CH3CH2)2N—],3.45[br s,4H,(CH3CH2)2N—],3.93(s,3H,3′-OCH3),3.95(s,3H,4′-OCH3),4.43(s,2H,—SCH2—),6.80(d,1H,5.61 Hz,5′-H),7.24(dd,1H,8.18 Hz,1.2 Hz,6-H),7.54(d,1H,8.19 Hz,7-H),7.59(d,1H,1.2 Hz,4-H),8.25(d,1H,5.60 Hz,6′-H),12.5(br s,1H,—NH—)
C20H24N4O3S
59.98
, 百拇医药
(59.90
6.04
6.15
13.09
13.87)
6c
62.5
112~114
3423,2976,1620,1068
1.20[br s,6H,(CH3CH2)2N—],3.40[br s,4H,(CH3CH2)2N—],3.83(s,3H,3′-OCH3),3.86(s,3H,4′-CH3),4.80(dd,2H,13.0 Hz,—SOCH2—),6.79(d,1H,5.58 Hz,5′-H),7.32(dd,1H,8.34 Hz,1.14 Hz,6-H),7.65(d,1H,8.34 Hz,7-H),7.70(d,1H,1.14 Hz,4-H),8.13(d,1H,5.58 Hz,6′-H),12.46(br s,1H,—NH—)
, 百拇医药
C20H24N4O4S
57.67
(57.76
5.85
5.74
13.46
13.47)
to be continued
Continued Tab.1 Compd.
Yield/%
mp/℃
, 百拇医药
IR(KBr)/cm-1
1H-NMR(CDCl3,TMS)δ
Formula
Elemental analysis/%(Found/Calc.)
C
N
H
5d
52.5
67~70
, 百拇医药
3346,2927,1630,1456
0.95(t,3H,7.27 Hz,CH3CH2—),1.45(m,2H,CH3CH2CH2—),1.62(m,2H,—NHCH2CH2CH2—),3.48(q,2H,6.76 Hz,—NHCH2—),3.93(s,3H,3′-OCH3),3.95(s,3H,4′-OCH3),4.42(s,2H,—SCH2—),6.41(br s,1H,—CONH—),6.87(d,1H,5.55 Hz,5′-H),7.51(d,1H,8.4 Hz,7-H),7.59(dd,1H,8.4 Hz,6-H),8.00(d,1H,1.41 Hz,4-H),8.24(d,1H,5.55 Hz,6′-H,12.1(br s,1H,—NH—)
, 百拇医药
C20H24N4O3S
59.98
(59.76
6.04
6.20
13.99
14.05)
6d
43.3
115~116
3340,2933,1638,1069
, http://www.100md.com
0.96(t,3H,7.30 Hz,CH3CH2—),1.41(m,2H,CH3CH2—),1.64(m,2H,—NHCH2CH2CH2—),3.48(q,2H,6.24 Hz,—NHCH2—),3.82(s,3H,3′-OCH3),3.84(s,3H,4′-OCH3),4.84(dd,2H,12.9 Hz,—SOCH2—),6.74(br s,1H,—CONH—),6.75(d,1H,5.55 Hz,5′-H),7.51(d,1H,8.13 Hz,7-H),7.66(d,1H,8.13 Hz,6-H),7.97(s,1H,4-H),8.10(d,1H,5.55 Hz,6′-H,12.43(br s,1H,—NH—)
C20H24N4O4S
, 百拇医药
57.67
(57.60
5.85
5.93
13.46
13.57)
5e
65.5
103~106
3368,3010,2937,1605,1445
1.64[br s,6H,—(CH2)3—],3.60(br s,4H,—CH2NHCH2—),3.93(s,3H,3′-OCH3),3.95(s,3H,4′-OCH3),4.40(s,2H,—SCH2—),6.88(d,1H,5.64 Hz,5′-H),7.23(d,1H,8.2 Hz,7-H),7.53(d,1H,8.2 Hz,6-H),7.61(s,1H,4-H),8.26(d,1H,5.64 Hz,6′-H),12.4(br s,1H,—NH—)
, 百拇医药
C21H24N4O3S
61.14
(61.20
5.87
5.80
13.59
13.67)
6e
37.9
110~112
3431,2938,2854,1620,1068
, 百拇医药
1.60[br s,6H,—(CH2)3—],3.64(br s,4H,—CH2NHCH2—),3.84(s,3H,3′-OCH3),3.94(s,3H,4′-OCH3),4.79(dd,2H,13.0 Hz,—SOCH2—),6.80(d,1H,5.55 Hz,5′-H),7.35(d,1H,8.3 Hz,7-H),7.63(d,1H,8.3 Hz,6-H),7.75(s,1H,4-H),8.15(d,1H,5.52 Hz,6′-H),12.4(br s,1H,—NH—)
C21H24N4O4S
58.86
(58.95
, http://www.100md.com
5.65
5.64
13.06
13.12)
5f
36.7
113~115
3341,3002,2946,1631,1425
3.94(s,3H,3′-OCH3),3.96(s,3H,4′-OCH3),4.41(s,2H,—SCH2—),4.69(d,2H,5.61 Hz,PhCH2—),6.55(t,1H,5.61 Hz,—CONH—),6.59(d,1H,5.62 Hz,5′-H),7.30(m,5H,Ph—),7.54(d,1H,8.37 Hz,7-H),7.62(dd,1H,8.37 Hz,1.40 Hz,6-H),8.05(d,1H,1.40 Hz,4-H),8.27(d,1H,5.61 Hz,6′-H),12.60(br s,1H,—NH—)
, 百拇医药
C23H22N4O3S
63.57
(63.50
5.11
5.20
12.90
13.00)
6f
44.4
136~138
3331,3012,1638,1071
, http://www.100md.com
3.79(s,3H,3′-OCH3),3.81(s,3H,4′-OCH3),4.66(d,2H,5.61 Hz,PhCH2—),4.80(dd,2H,13.02 Hz,—SOCH2—),6.71(d,1H,5.64 Hz,5′-H),6.96(br s,1H,—CONH—),7.30(m,5H,Ph—),7.54(d,1H,8.35 Hz,7-H),7.70(dd,1H,8.35 Hz,1.35 Hz,6-H),8.02(d,1H,1.35 Hz,4-H),8.06(d,1H,5.64 Hz,6′-H),12.55(br s,1H,—NH—)
C23H22N4O4S
61.31
(61.35
, 百拇医药
4.93
5.04
12.44
12.30)
2 药理实验
将体重为180~250 g Wistar大鼠42只随机分成14组,每组3只,禁食但可自由饮水24 h后,在乙醚麻醉下,给大鼠行开腹手术,按Goto和Kishi方法结扎幽门和喷门窦与体部的连接处.结扎后,立即经十二指肠给各组动物按15 mg/kg剂量分别注射试验样品、阳性对照品(泮托拉唑)和阴性对照品(5% Gum).给药4 h后,将各组动物处死,解剖出食管,肉眼观察食管损伤情况.判断标准为:食道大部分出血坏死,损伤长度在55 mm以上为强阳性(+ + +);食道中部约全长1/2出血坏死或充血,损伤长度在30~54 mm为中强阳性(+ +);食道中部点状出血坏死或充血,损伤长度在29 mm以下为弱强阳性(+);食道全长光滑无色变为阴性(-).实验结果见表2.药理试验结果显示:化合物(5b),(6b),(6d)均有明显的抑制胃酸分泌作用,其中化合物(6d)作用最强.
, 百拇医药
Tab.2 The effect of benzimidazole derivatives on reflux esophagitis of Wistar mice Compd.
The degree of esophage damage
Compd.
The degree of esophage damage
1
2
3
1
2
3
, http://www.100md.com
5a
—
+ + +
+ + +
6d
—
—
—
6a
+
+ +
+ + +
5e
+ + +
, 百拇医药
+ + +
+ + +
5b
—
—
+ +
6e
+ +
+ + +
+ + +
6b
—
—
, 百拇医药 + + +
5f
—
+ + +
+ + +
5c
+
+ +
+ + +
6f
+ + +
+ + +
+ + +
, 百拇医药
6c
+ +
+ + +
+ + +
Panto
—
—
—
5d
+
+ + +
+ +
5%Gum
, 百拇医药
+ +
+ +
+ + +
致谢:沈阳药科大学测试中心、辽宁省理化测试中心、化工部感光材料研究院测试中心代测各种光谱,辽宁省基础医学研究所药理研究室郭季安教授、王晓秋老师代测药理活性. 参 考 文 献
1.Hunt RH,Mowden CW,Jones DB,et al.The correlation between acid suppression and peptic ulcer healing.Scand J Gastroenterol,1986,21(suppl 125):22~31
2.Edd CR,Michael AR.The mechanism and structure of the gastric H+,K+-ATP ase.Annu Rev Physiol,1990,52:321~344
, http://www.100md.com
3.Black JW,Duncan WAM,Durant CJ,et al.Definition and antagonism of histamine H2-receptors.Nature,1972,236(5347):385~390
4.Sachs G,Carlsson E,Lindberg P,et al.Gastric H+,K+-ATPase as therapeutic target.Annu Rev Pharmacol Toxical,1988,28:269~284
5.Lind berg P,Nordberg P,Alminger T,et al.The mechanism of action of the gastric acid secretion inhibitor omeprazole.J Med Chem,1986,29(8):1327~1329
, http://www.100md.com
6.高芳华,黄立信.棘球蚴病化学药物研究:苯并咪唑类化合物的合成.中国医药工业杂志,1989,20(3):110~115
7.Kohl B,Sturm E,Senn-Bilfinger J.(H\++,K\++)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazole 4.A novel series of dimethoxylpyridyl-substituted inhibitors with enhanced selectivity.J Med Chem,1992,35(6):1049~1057
收稿日期:1999-01-05, 百拇医药(黄国宾 程卯生 黄惠琴 沈建民1)
单位:沈阳药科大学科研处合成二室,沈阳 110015
关键词:H+/K+-ATP酶抑制剂;苯并咪唑类衍生物;抑制胃酸分泌
中国药物化学杂志/990203摘 要 H+/K+-ATP酶是胃酸分泌的最后环节,在合成H+/K+-ATP酶抑制剂泮托拉唑的基础上,设计合成了12个未见文献报道的苯并咪唑类衍生物,经红外光谱、核磁共振氢谱和元素分析确定了结构.初步药理筛选实验表明:化合物(5b),(6b),(6d)具有抑制胃酸分泌的作用,其中化合物(6d)作用最强.
Studies on H+/K-ATPase Inhibitors Benzimidazole Derivatives
, 百拇医药
Huang Guobin,Cheng Maosheng,Huang Huiqing,Shen Jianmin
Institute of Materia Medica,Shenyang Pharmaceutical University,Shenyang 110015
Abstract H+/K-ATPase is the last passageway of gastric acid secretion.On the basis of synthesis of the H+K-ATPase inhibitor pantoprazole,twelve benzimidazole derivatives were synthesized for the first time,and their structures were proved by IR,1H-NMR and elementary analysis.Their antisecretory activities were evaluated in vivo,the compounds (5b),(6b) and (6d) have antisecretory activities and compound (6d) was the most potent.
, 百拇医药
Key words H+K-ATPase inhibitors;benzimidazole derivatives;inhibiting gastric acid secretion
消化性溃疡疾病是常见的多发病之一,它与胃酸分泌过多有着直接的关系,迅速有效地抑制胃酸分泌是目前治疗消化性溃疡疾病的重要手段〔1〕.胃酸的分泌是由于胃壁细胞膜上的毒蕈碱受体(MR)、胃泌素受体(GR)和组胺H2受体(H2R)分别受到乙酰胆碱、胃泌素和组胺的刺激,引起胃壁细胞分泌胃酸〔2,3〕.分泌出的胃酸必需依靠H+/K+-ATP酶的转运功能把胃壁细胞中的H+转运到胃腔中形成胃酸〔4〕.因此,抑制H+/K+-ATP酶的活性就能有效地控制胃酸分泌.国内外对H+/K+-ATP酶抑制剂进行了广泛的研究,先后上市了奥美拉唑(omeprazole,1)、兰索拉唑(lansoprazole,2)和泮托拉唑(pantoprazole,3),从这三种药物的化学结构看,它们均是吡啶甲基亚磺酰基苯并咪唑类化合物,其本身并无抑制H+/K+-ATP酶的活性,
, 百拇医药
只是在酸性条件下质子化,转变为具有抑制H+/K+-ATP酶活性的化合物次磺酰胺(sulphenamide),它迅速与H+/K+-ATP酶上的半胱氨酸的巯基结合形成二硫键,从而使酶失活〔5〕.研究发现,吡啶环上取代基对活性影响较大,凡能增加吡啶环pKa值的基团将能增加化合物的活性,但pKa值的增加会使作用的靶位专一性降低.由于对苯并咪唑环上的取代基对活性的影响研究较少,因此,本文在合成泮托拉唑的基础上,保留其基本结构,只改变苯并咪唑5-位取代基,用N-取代氨甲酰基[R1R2NC(O)—]代替二氟甲氧基[F2HCO—],设计合成了12个未见文献报道的化合物,以期找到比较稳定和活性高的化合物.合成路线见图1.
, 百拇医药
Fig.1 The route of synthesis of benzimidazole derivatives
1 合成实验
熔点用毛细管法测定,温度未校正.核磁共振氢谱用Bluker AXR-300测定.红外光谱用Bluker IFS 55测定.元素分析用Carlo Erba 1106测定.柱色谱硅胶为青岛海洋化工厂产品.
1.1 3,4-二氨基-N-取代苯甲酰胺(1a~1f)的制备
按文献[6]的方法制备.
1.2 2-巯基-5-取代氨甲酰基-1H-苯并咪唑(2a~2f)的制备
将化合物(1a~1f)0.01 mol加至0.01 mol氢氧化钾、5 mL水和20mL乙醇组成的混合液中,加入二硫化碳0.8 mL,加热回流4 h.用2 mol/L盐酸调pH 3~4,抽滤,粗品用乙醇重结晶,得白色固体.化合物(2a):mp 250℃以上,收率为50.3%;化合物(2b):mp 250℃以上,收率为84.2%;化合物(2c):mp 200~202℃,收率为42.3%;化合物(2d):mp 236~237℃,收率为80%;化合物(2e):mp 231~232℃,收率为37.4%;化合物(2f):mp 228~230℃,收率为75.9%.
, 百拇医药
1.3 2-氯甲基-3,4-二甲氧基吡啶盐酸盐(4)的制备
按文献〔7〕的方法制备.
1.4 5-(N-取代)氨甲酰基-2-[[(3′,4′-二甲氧基-2′-吡啶基)-甲基]-巯基]-1H-苯并咪唑(5a~5f)的合成
将化合物(2a~2f)0.022 mol及化合物(4)0.022 mol加至1.94 g(0.0484 mol)氢氧化钠的30 mL乙醇溶液中,加热回流6 h.减压蒸去乙醇,二氯甲烷萃取(30 mL×3),无水硫酸钠干燥,减压浓缩,残余物经硅胶柱层析[展开剂:氯仿-甲醇(v∶v=95∶5)]得白色固体.熔点、收率和波谱数据见表1.
1.5 5-(N-取代)氨甲酰基-2-[[(3′,4′-二甲氧基-2′-吡啶基)-甲基]-亚磺酰基]-1H-苯并咪唑(6a~6f)的合成
, 百拇医药
将化合物(5a~5f)0.01 mol溶于20 mL氯仿中,磁力搅拌,冰盐浴冷至-10℃,滴加1.73 g(0.01 mol)间氯过氧苯甲酸的10 mL氯仿溶液,反应5 h.依次加入1 mL三乙胺、5 mL 10%硫代硫酸钠溶液和5 mL饱和碳酸钠溶液,搅拌10 min,分取有机层.水洗,饱和碳酸钠溶液(20 mL)洗,无水硫酸钠干燥,浓缩,残余物经硅胶柱层析[展开剂:氯仿-甲醇(v∶v=95∶5)]得白色固体.熔点、收率和波谱数据见表1.
Tab.1 The physical data and spectrum data of compounds(5a~5f)and(6a~6f) Compd.
Yield/%
mp/℃
IR(KBr)/cm-1
, 百拇医药
1H-NMR(CDCl3,TMS)δ
Formula
Elemental analysis/%(Found/Calc.)
C
N
H
5a
62.5
137~138
3357,2942,1640,1415
3.04(d,3H,4.8 Hz,—NCH3),3.94(s,3H,3′-OCH3),3.96(s,3H,4′-OCH3),4.42(s,2H,—SCH2),6.43(br s,1H,—CONH—),6.88(d,1H,5.67 Hz,5′-H),7.52(d,1H,8.37 Hz,7-H),7.59(dd,1H,8.37,0.9 Hz,6-H),8.01(d,1H,0.9 Hz,4-H),8.26(d,1H,5.67 Hz,6′-H),12.1(br s,1H,—NH—)
, 百拇医药
C17H18N4O3S
56.96
(56.80
5.07
5.13
15.66
15.60)
6a
40.1
165~167
3385,1642,1071
, 百拇医药
3.04(d,3H,4.74 Hz,—NCH3),3.86(s,3H,3′-OCH3),3.87(s,3H,4′4′-OCH3),4.84(dd,2H,12.96 Hz,—SOCH2),6.70(br s,1H,—CONH—),6.79(d,1H,5.61 Hz,5′-H),7.57(d,1H,7.17 Hz,7-H),7.69(d,1H,7.17 Hz,6-H),7.99(s,1H,4-H),8.13(d,1H,5.61 Hz,6′-H),12.3(br s,1H,—NH—)
C17H18N4O4S
54.53
(54.50
4.85
, http://www.100md.com
4.91
14.97
14.86)
6b
38.4
105~106
3300,2973,1634,1067
1.30[d,6H,6.54 Hz,(CH3)2C—],3.85(s,3H,3′-OCH3),3.86(s,3H,4′-OCH3),4.30(m,1H,—CH—),4.82(dd,2H,13.05 Hz,—SOCH2),6.17(d,1H,7.56 Hz,—CONH—),6.78(d,1H,5.58 Hz,5′-H),7.60(d,1H,8.37 Hz,7-H),7.69(d,1H,8.37 Hz,6-H),8.01(s,1H,4-H),8.14(d,1H,5.58 Hz,6′-H),12.5(br s,1H,—NH—)
, 百拇医药
C19H22N4O4S
56.69
(56.73
5.51
5.43
13.93
13.96)
5c
70.0
60~61
3427,2981,2873,1617,1439
, http://www.100md.com
1.20[br s,6H,(CH3CH2)2N—],3.45[br s,4H,(CH3CH2)2N—],3.93(s,3H,3′-OCH3),3.95(s,3H,4′-OCH3),4.43(s,2H,—SCH2—),6.80(d,1H,5.61 Hz,5′-H),7.24(dd,1H,8.18 Hz,1.2 Hz,6-H),7.54(d,1H,8.19 Hz,7-H),7.59(d,1H,1.2 Hz,4-H),8.25(d,1H,5.60 Hz,6′-H),12.5(br s,1H,—NH—)
C20H24N4O3S
59.98
, 百拇医药
(59.90
6.04
6.15
13.09
13.87)
6c
62.5
112~114
3423,2976,1620,1068
1.20[br s,6H,(CH3CH2)2N—],3.40[br s,4H,(CH3CH2)2N—],3.83(s,3H,3′-OCH3),3.86(s,3H,4′-CH3),4.80(dd,2H,13.0 Hz,—SOCH2—),6.79(d,1H,5.58 Hz,5′-H),7.32(dd,1H,8.34 Hz,1.14 Hz,6-H),7.65(d,1H,8.34 Hz,7-H),7.70(d,1H,1.14 Hz,4-H),8.13(d,1H,5.58 Hz,6′-H),12.46(br s,1H,—NH—)
, 百拇医药
C20H24N4O4S
57.67
(57.76
5.85
5.74
13.46
13.47)
to be continued
Continued Tab.1 Compd.
Yield/%
mp/℃
, 百拇医药
IR(KBr)/cm-1
1H-NMR(CDCl3,TMS)δ
Formula
Elemental analysis/%(Found/Calc.)
C
N
H
5d
52.5
67~70
, 百拇医药
3346,2927,1630,1456
0.95(t,3H,7.27 Hz,CH3CH2—),1.45(m,2H,CH3CH2CH2—),1.62(m,2H,—NHCH2CH2CH2—),3.48(q,2H,6.76 Hz,—NHCH2—),3.93(s,3H,3′-OCH3),3.95(s,3H,4′-OCH3),4.42(s,2H,—SCH2—),6.41(br s,1H,—CONH—),6.87(d,1H,5.55 Hz,5′-H),7.51(d,1H,8.4 Hz,7-H),7.59(dd,1H,8.4 Hz,6-H),8.00(d,1H,1.41 Hz,4-H),8.24(d,1H,5.55 Hz,6′-H,12.1(br s,1H,—NH—)
, 百拇医药
C20H24N4O3S
59.98
(59.76
6.04
6.20
13.99
14.05)
6d
43.3
115~116
3340,2933,1638,1069
, http://www.100md.com
0.96(t,3H,7.30 Hz,CH3CH2—),1.41(m,2H,CH3CH2—),1.64(m,2H,—NHCH2CH2CH2—),3.48(q,2H,6.24 Hz,—NHCH2—),3.82(s,3H,3′-OCH3),3.84(s,3H,4′-OCH3),4.84(dd,2H,12.9 Hz,—SOCH2—),6.74(br s,1H,—CONH—),6.75(d,1H,5.55 Hz,5′-H),7.51(d,1H,8.13 Hz,7-H),7.66(d,1H,8.13 Hz,6-H),7.97(s,1H,4-H),8.10(d,1H,5.55 Hz,6′-H,12.43(br s,1H,—NH—)
C20H24N4O4S
, 百拇医药
57.67
(57.60
5.85
5.93
13.46
13.57)
5e
65.5
103~106
3368,3010,2937,1605,1445
1.64[br s,6H,—(CH2)3—],3.60(br s,4H,—CH2NHCH2—),3.93(s,3H,3′-OCH3),3.95(s,3H,4′-OCH3),4.40(s,2H,—SCH2—),6.88(d,1H,5.64 Hz,5′-H),7.23(d,1H,8.2 Hz,7-H),7.53(d,1H,8.2 Hz,6-H),7.61(s,1H,4-H),8.26(d,1H,5.64 Hz,6′-H),12.4(br s,1H,—NH—)
, 百拇医药
C21H24N4O3S
61.14
(61.20
5.87
5.80
13.59
13.67)
6e
37.9
110~112
3431,2938,2854,1620,1068
, 百拇医药
1.60[br s,6H,—(CH2)3—],3.64(br s,4H,—CH2NHCH2—),3.84(s,3H,3′-OCH3),3.94(s,3H,4′-OCH3),4.79(dd,2H,13.0 Hz,—SOCH2—),6.80(d,1H,5.55 Hz,5′-H),7.35(d,1H,8.3 Hz,7-H),7.63(d,1H,8.3 Hz,6-H),7.75(s,1H,4-H),8.15(d,1H,5.52 Hz,6′-H),12.4(br s,1H,—NH—)
C21H24N4O4S
58.86
(58.95
, http://www.100md.com
5.65
5.64
13.06
13.12)
5f
36.7
113~115
3341,3002,2946,1631,1425
3.94(s,3H,3′-OCH3),3.96(s,3H,4′-OCH3),4.41(s,2H,—SCH2—),4.69(d,2H,5.61 Hz,PhCH2—),6.55(t,1H,5.61 Hz,—CONH—),6.59(d,1H,5.62 Hz,5′-H),7.30(m,5H,Ph—),7.54(d,1H,8.37 Hz,7-H),7.62(dd,1H,8.37 Hz,1.40 Hz,6-H),8.05(d,1H,1.40 Hz,4-H),8.27(d,1H,5.61 Hz,6′-H),12.60(br s,1H,—NH—)
, 百拇医药
C23H22N4O3S
63.57
(63.50
5.11
5.20
12.90
13.00)
6f
44.4
136~138
3331,3012,1638,1071
, http://www.100md.com
3.79(s,3H,3′-OCH3),3.81(s,3H,4′-OCH3),4.66(d,2H,5.61 Hz,PhCH2—),4.80(dd,2H,13.02 Hz,—SOCH2—),6.71(d,1H,5.64 Hz,5′-H),6.96(br s,1H,—CONH—),7.30(m,5H,Ph—),7.54(d,1H,8.35 Hz,7-H),7.70(dd,1H,8.35 Hz,1.35 Hz,6-H),8.02(d,1H,1.35 Hz,4-H),8.06(d,1H,5.64 Hz,6′-H),12.55(br s,1H,—NH—)
C23H22N4O4S
61.31
(61.35
, 百拇医药
4.93
5.04
12.44
12.30)
2 药理实验
将体重为180~250 g Wistar大鼠42只随机分成14组,每组3只,禁食但可自由饮水24 h后,在乙醚麻醉下,给大鼠行开腹手术,按Goto和Kishi方法结扎幽门和喷门窦与体部的连接处.结扎后,立即经十二指肠给各组动物按15 mg/kg剂量分别注射试验样品、阳性对照品(泮托拉唑)和阴性对照品(5% Gum).给药4 h后,将各组动物处死,解剖出食管,肉眼观察食管损伤情况.判断标准为:食道大部分出血坏死,损伤长度在55 mm以上为强阳性(+ + +);食道中部约全长1/2出血坏死或充血,损伤长度在30~54 mm为中强阳性(+ +);食道中部点状出血坏死或充血,损伤长度在29 mm以下为弱强阳性(+);食道全长光滑无色变为阴性(-).实验结果见表2.药理试验结果显示:化合物(5b),(6b),(6d)均有明显的抑制胃酸分泌作用,其中化合物(6d)作用最强.
, 百拇医药
Tab.2 The effect of benzimidazole derivatives on reflux esophagitis of Wistar mice Compd.
The degree of esophage damage
Compd.
The degree of esophage damage
1
2
3
1
2
3
, http://www.100md.com
5a
—
+ + +
+ + +
6d
—
—
—
6a
+
+ +
+ + +
5e
+ + +
, 百拇医药
+ + +
+ + +
5b
—
—
+ +
6e
+ +
+ + +
+ + +
6b
—
—
, 百拇医药 + + +
5f
—
+ + +
+ + +
5c
+
+ +
+ + +
6f
+ + +
+ + +
+ + +
, 百拇医药
6c
+ +
+ + +
+ + +
Panto
—
—
—
5d
+
+ + +
+ +
5%Gum
, 百拇医药
+ +
+ +
+ + +
致谢:沈阳药科大学测试中心、辽宁省理化测试中心、化工部感光材料研究院测试中心代测各种光谱,辽宁省基础医学研究所药理研究室郭季安教授、王晓秋老师代测药理活性. 参 考 文 献
1.Hunt RH,Mowden CW,Jones DB,et al.The correlation between acid suppression and peptic ulcer healing.Scand J Gastroenterol,1986,21(suppl 125):22~31
2.Edd CR,Michael AR.The mechanism and structure of the gastric H+,K+-ATP ase.Annu Rev Physiol,1990,52:321~344
, http://www.100md.com
3.Black JW,Duncan WAM,Durant CJ,et al.Definition and antagonism of histamine H2-receptors.Nature,1972,236(5347):385~390
4.Sachs G,Carlsson E,Lindberg P,et al.Gastric H+,K+-ATPase as therapeutic target.Annu Rev Pharmacol Toxical,1988,28:269~284
5.Lind berg P,Nordberg P,Alminger T,et al.The mechanism of action of the gastric acid secretion inhibitor omeprazole.J Med Chem,1986,29(8):1327~1329
, http://www.100md.com
6.高芳华,黄立信.棘球蚴病化学药物研究:苯并咪唑类化合物的合成.中国医药工业杂志,1989,20(3):110~115
7.Kohl B,Sturm E,Senn-Bilfinger J.(H\++,K\++)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazole 4.A novel series of dimethoxylpyridyl-substituted inhibitors with enhanced selectivity.J Med Chem,1992,35(6):1049~1057
收稿日期:1999-01-05, 百拇医药(黄国宾 程卯生 黄惠琴 沈建民1)